Loading company…
ID 204432603 · FY 2018–2024 · 7 years
Subsidiary of შეზღუდული პასუხისმგებლობისსაზოგადოება "ვორლდვაიდ კლინიკალ თრაიალსრუსეთი" (100.0%)
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Margins | |||||||
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 32.7% |
| EBITDA Margin | 5.6% | 2.6% | -2.2% | -15.5% | -9.3% | -0.5% | 2.9% |
| EBITDAR | 421 | 386 | 263 | -3 | 79 | 452 | 681 |
| EBITDAR Margin | 14.2% | 11.4% | 7.0% | -0.1% | 1.6% | 7.9% | 10.6% |
| EBIT Margin | 3.0% | 0.5% | -4.5% | -18.3% | -12.5% | -0.9% | 1.2% |
| Net Profit Margin | 4.7% | 1.5% | -1.1% | -15.6% | -8.0% | -1.7% | 1.5% |
| Operating Expense % of Sales | 94.4% | 97.4% | 102.2% | 115.5% | 109.3% | 100.5% | 29.8% |
| Returns | |||||||
| Return on Assets (ROA) | 19.6% | 6.4% | -5.4% | -66.7% | -41.2% | -9.5% | 9.6% |
| Return on Equity (ROE) | 23.9% | 8.2% | -7.3% | N/A | N/A | N/A | N/A |
| ROIC [EBIT / Invested Capital] | 24.8% | 3.1% | -37.8% | N/A | N/A | N/A | N/A |
| Leverage & liquidity | |||||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | -0.00x | -0.00x | -0.00x | -0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | N/A | N/A | N/A | N/A | 0.00x |
| Equity-to-Assets | 81.7% | 78.2% | 74.6% | -4.6% | -45.8% | -51.7% | -43.4% |
| Net Debt | -219 | -72 | -147 | -91 | -199 | -199 | -203 |
| Cash & Equivalents | 219 | 72 | 147 | 91 | 199 | 199 | 203 |
| Total Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Efficiency & working capital | |||||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 11.51x | 6.76x | 17.22x | 20.64x | 38.40x | 22.21x | 41.16x |
| Days Sales Outstanding (DSO) | 31.7 | 54.0 | 21.2 | 17.7 | 9.5 | 16.4 | 8.9 |
| Payables Turnover | N/A | N/A | N/A | N/A | N/A | N/A | 106.38x |
| Days Payable Outstanding (DPO) | N/A | N/A | N/A | N/A | N/A | N/A | 3.4 |
| Cash Conversion Cycle | 31.7 days | 54.0 days | 21.2 days | 17.7 days | 9.5 days | 16.4 days | 5.4 days |
| Asset Turnover | 4.16x | 4.17x | 4.74x | 4.29x | 5.13x | 5.57x | 6.38x |
| Cash flow & dividends | |||||||
| Operating Cash Flow | 94 | -147 | 75 | 72 | 107 | 0 | 205 |
| Free Cash Flow (OCF − Capex proxy) | 94 | -147 | 75 | 72 | 107 | 0 | 55 |
| Cash Conversion (OCF / EBITDA) | 57.1% | -165.7% | N/A | N/A | N/A | N/A | 110.5% |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Companies sharing this sector, ranked by how close their latest revenue is to this one — not a curated comp set.
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Ownership & directors from companyinfo.ge (public corporate registry).